Skip to search formSkip to main contentSkip to account menu

atorvastatin

Known as: (betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid, (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid 
A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which… 
National Institutes of Health

Related topics

Related topics

36 relations
Amlodipine / atorvastatinAmlodipine 5 MG / atorvastatin 80 MG Oral Tablet [Caduet]Atorvastatin SodiumAtorvastatin calcium

Broader (2)

Anticholesteremic AgentsPyrroles

Narrower (6)

CI 981CaduetLipitorLiptruzet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
High-dose atorvastatin after stroke or transient ischemic attack.
BACKGROUND Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they… 
Highly Cited
2006
Highly Cited
2006
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute.
Highly Cited
2005
Highly Cited
2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
CONTEXT Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied… 
Highly Cited
2005
Highly Cited
2005
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
Highly Cited
2005
Highly Cited
2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Highly Cited
2004
Highly Cited
2004
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Review
2003
Review
2003
Clinical Pharmacokinetics of Atorvastatin
Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease. Atorvastatin lowers plasma low-density… 
Highly Cited
2002
Highly Cited
2002
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may… 
Highly Cited
2002
Highly Cited
2002
Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may exert direct effects on vascular cells and beneficially… 
Highly Cited
2001
Highly Cited
2001
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study : A randomized… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)